Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Med Immune Inc history
Med Immune Inc company history timeline
In 1989, Molecular Vaccines, Inc changed its name to MedImmune, Inc.
During its early years, MedImmune also worked to develop and test CytoGam, a drug that attacks life-threatening cytomegalovirus infections that can occur in patients who have had kidney transplants or AIDS. FDA approval in 1991 won MedImmune international attention.
However, in 1993, an FDA panel unanimously rejected the drug, RespiGam, citing sloppy research as its reason for recommending further testing.
By late 1993, critics were pondering the erratic performance of MedImmune.
In 1995, the results of a fresh study were in, showing that RespiGam did work to prevent RSV. The next year, it went on the market, and MedImmune regained footing with investors.
The drug, Synagis, was approved by the FDA in the summer of 1998 and went on the market a few months later.
In 1999, the efficacy of the vaccine was reaffirmed after the first season's use.
In 1999, the company formed an alliance with Ixys, Inc., a privately held biopharmaceutical company, to develop new monoclonal antibodies.
1999: MedImmune enters oncology field when it buys pharmaceutical company United States Bioscience.
In 2000, MedImmune was performing clinical trials of the vaccine.
MedImmune hoped that one of its ventures, begun in 2000, would pan out and help keep the company's stock up.
In June 2007, the National Institutes of Health (NIH) began enrolling participants in a Phase 1 H5N1 study of an intranasal influenza vaccine candidate based on MedImmune's live, attenuated vaccine technology.
AstraZeneca presented the new MedImmune to investors on 7 December 2007.
In June 2009 it won a Department of Health and Human Services (HHS) contract, worth $90m.
MedImmune received approval from the United States FDA for its intranasal novel H1N1 influenza vaccine in September 2009.
But AstraZeneca said the deal would add to its cash earnings per share, excluding amortization, by 2009 and that it could achieve $500 million a year in cost savings.
Rate Med Immune Inc's efforts to communicate its history to employees.
Med Immune Inc jobs
Do you work at Med Immune Inc?
Does Med Immune Inc communicate its history to new hires?
Med Immune Inc competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Vertex Pharmaceuticals | 1989 | $11.0B | 3,400 | 121 |
| Merck | 1891 | $64.2B | 74,000 | 2,290 |
| Johnson & Johnson | 1886 | $88.8B | 134,500 | 1,468 |
| Ligand Pharmaceuticals | 1987 | $241.5M | 116 | - |
| Seagen | 1997 | $2.0B | 900 | - |
| Gilead Sciences | 1987 | $28.8B | 11,800 | 692 |
| Novavax | 1987 | $682.2M | 791 | 5 |
| Nanotherapeutics, Inc. | - | - | - | - |
| Elanco | 1954 | $4.4B | 10,200 | 107 |
| LSNE Contract Manufacturing | 1997 | $9.2M | 15 | - |
Med Immune Inc history FAQs
Zippia gives an in-depth look into the details of Med Immune Inc, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Med Immune Inc. The employee data is based on information from people who have self-reported their past or current employments at Med Immune Inc. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Med Immune Inc. The data presented on this page does not represent the view of Med Immune Inc and its employees or that of Zippia.
Med Immune Inc may also be known as or be related to Med Immune Inc.